Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind controlled study of adsorbed acellular pertussis (five-component), reduced diphtheria, and tetanus combined vaccine in participants aged 7 years and older
CTR20244440Phase 2Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in pertussis, diphtheria, Tetanus, sponsored by CanSino Biologics Inc.. Started Dec 2024; status: completed.
02
Drugs
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20244440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244440.